Last updated on November 2019

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia

Brief description of study

A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows:

Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment.

Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or refractory T-PLL.

Clinical Study Identifier: NCT03873493

Find a site near you

Start Over

Maxima Medisch Centrum /ID# 207989

Eindhoven, Netherlands
  Connect »